t
On 1 June 2023, Proteome Sciences plc repaid in full an outstanding loan and associated interest to Vulpes Investment Management Private Limited. The total amount repaid was £824,424, relating to a loan originally announced on 2 July 2018 and amended on 30 March 2022.
| Date | 1 Jun 2023 |
| Time | 09:43:29 |
| Category | Miscellaneous |
| ID | 3395B |
Annual Report and Accounts (to 2022-12-31)
1 June 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Repayment of Loan to Vulpes Investment Management Private Limited
The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling £824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.
|
Proteome Sciences plc |
||
|
Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer |
Tel: +44 (0)20 7043 2116 |
|
|
Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer |
|
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser & Broker) |
|
|
|
John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)
|
Tel: +44 (0) 20 3328 5656 |
|
|
|
||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.